Stanford University’s Innovative Medicines Accelerator and Intonation Research Laboratories (Intonation) form a collaboration to fight cancerous neuroendocrine tumors
Retrieved on:
Thursday, June 22, 2023
Health, Genetics, Other Health, Other Science, General Health, Research, Science, Heart, Endocrinology, Partnership, Stanford School, Stanford University, Intonation, Neoplasm, Glomus tumor, Cancer, IMA, Multimedia, Medicine, Doctor of Philosophy, Glioblastoma, Chemistry, Innovative Medicines Initiative, Patient, Chemical engineering, Drug discovery, Marc, Khosla, Ecosystem, Sarafan, Pharmaceutical industry, Management, Symbols of North and East Syria, MD
Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.
Key Points:
- Stanford University’s Innovative Medicines Accelerator (IMA) and Intonation Research Laboratories (Intonation) have formed a collaboration to develop treatments that target cancerous neuroendocrine tumors, or tumors that form from hormone-releasing cells.
- “I’m excited about this collaboration with Intonation Research Laboratories, which has the potential to speed the translation of promising research into urgently needed new treatments and therapies,” said Marc Tessier-Lavigne , president of Stanford University.
- “We hope to greatly accelerate our drug development program and deliver transformative treatments to patients burdened with neuroendocrine tumors,” he said.
- “The IMA continues to seek high-quality partners in our mission as an accelerator,” said Khosla, the Marc and Jennifer Lipschultz Director of the Stanford Innovative Medicines Accelerator.